Troponin and cardiomyopathy

Audrey N Chang1, Michelle S Parvatiyar, James D Potter

  • 1Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Room 6085A RMSB,1600 NW 10th Avenue, Miami, FL 33136, USA.

Insights

Genetic mutations in the troponin complex cause distinct cardiomyopathies by altering cardiac muscle contraction energetics. This review highlights in vivo studies of these troponin (TP) mutations and their effects.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Muscle Physiology

Background:

  • The troponin complex is crucial for sensing calcium (Ca2+) and regulating cardiac muscle contraction.
  • Genetic mutations in troponin lead to distinct cardiomyopathies, including hypertrophic (HCM), restrictive (RCM), and dilated (DCM) forms.
  • Decades of research have elucidated troponin's function and the impact of its mutations.

Purpose of the Study:

  • To review in vivo studies examining the effects of troponin mutations on cardiac muscle energetics and remodeling.
  • To discuss how genetic mutations in troponin contribute to the development of cardiomyopathies.
  • To suggest future research directions for understanding troponin's role in cardiac muscle regulation.

Main Methods:

  • Review of in vivo studies focusing on troponin mutation effects.
  • Analysis of functional studies and genetic methods.
  • Examination of alterations in cellular signaling and protein expression.

Main Results:

  • Troponin mutations significantly alter cardiac energetics.
  • These mutations promote characteristic pathological remodeling in cardiomyopathies.
  • Multiple molecular pathways contribute to hypertrophy and dilation in genetic cardiomyopathies.

Conclusions:

  • In vivo studies provide critical insights into the functional consequences of troponin mutations.
  • Understanding troponin's complex regulation is key to deciphering cardiac muscle contraction.
  • Further research is needed to fully elucidate the mechanisms underlying genetic cardiomyopathies related to troponin.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...